Published TCIMAIL newest issue No.196
Maximum quantity allowed is 999
CAS RN: 93957-55-2 | Produkte #: F0820
Fluvastatin Sodium Salt
Reinheit: >98.0%(HPLC)(N)
Einheit | Stückpreis | Belgien | Japan* | Menge |
---|---|---|---|---|
1G |
€68.00
|
1 | 6 |
|
5G |
€238.00
|
1 | 10 |
|
*In Belgien verfügbare Lagerbestände werden in 1 bis 3 Tagen geliefert.
*In Japan verfügbare Lagerbestände werden in 1 bis 2 Wochen geliefert. (unter Ausschluss von regulierten Artikeln und Trockeneislieferungen).
Ergänzende Produktinformation:
Previously this product had been labeled as a hydrate form both in product name and molecular formula. The hydrate form had no exclusive CAS RN and used to share the same CAS RN as the anhydrous form.
To avoid any misleading information and since moisture in product is considered as an impurity, we have decided to remove the term 'Hydrate' from product name and 'xH2O' from the molecular formula for such products.
Please use it at ease since there is no difference in product quality, even if you see the previous indications on a part of label.
Artikel # | F0820 |
Reinheit / Analysenmethode | >98.0%(HPLC)(N) |
Summenformel / Molekülmasse | C__2__4H__2__5FNNaO__4 = 433.46 |
Physikalischer Zustand (20 °C) | Solid |
Lagerungstemperatur | Refrigerated (0-10°C) |
Zu vermeidende Bedingungen | Heat Sensitive |
CAS RN | 93957-55-2 |
Verwandte CAS RN | 93957-54-1 |
PubChem-Stoff-ID | 160870917 |
Merck-Index (14) | 4218 |
MDL-Nummer | MFCD00929076 |
Appearance | Light orange to Yellow to Green powder to crystal |
Purity(HPLC) | min. 98.0 area% |
Purity(with Total Nitrogen) | min. 98.0 %(calcd.on anh.substance) |
Water | max. 6.0 % |
Löslichkeit (löslich in) | Methanol |
RTECS # | MJ9675100 |
HS-Nr. (Import / Export) (TCI-E) | 2933998090 |
References
- Inhibition of cholesterol synthesis ex vivo and in vivo by fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase
- Structural mechanism for statin inhibition of HMG-CoA reductase
- Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits
- In vitro comparative inhibition profiles of major human drug metabolizing cytochrome P450 isoenzymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors
- The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions
Artikel / Broschüren
[Research Articles] Ni/Cu-Catalyzed Defluoroborylation of Fluoroarenes
Sicherheitsdatenblatt (SDB)
Das angeforderte SDB ist nicht verfügbar.
Bitte Kontaktieren Sie uns für mehr Informationen.
Spezifikationsdokumenten
AZ & andere Zertifikate
Muster-AZ
Ein Muster-AZ für dieses Produkt ist zur Zeit nicht verfügbar.
Analytische Diagramme
Das angeforderte Analysediagramm ist nicht verfügbar. Wir entschuldigen uns für die Unannehmlichkeiten.